The regulation of prescription opioids: walking the tight rope

处方类阿片药物的监管:如履薄冰

阅读:1

Abstract

Prescription opioid misuse is widely rampant and increasing worldwide. Similar rising trends with reports of patients suffering from prescription opioid dependence are being reported from India. Unregulated prescription of opioids as pain-killers in the US contributed to onset of the ‘epidemic’ of prescription opioid misuse. Pain is a multidimensional and complex experience that has physical, social, spiritual and psychological aspects. Ensuring availability of opioids for treatment of chronic pain conditions is crucial. WHO estimates that 20 million people required end-of-life palliative care, of whom 78 % lived in low and middle income countries. India ranks among the lowest, with only 0.22% citizens having access to opioids for pain relief. While ensuring availability of prescription opioids for pain relief is crucial, it needs close monitoring and regulation as epidemic of prescription opioid misuse was fuelled by illicit marketing of pharmaceutical opioids. Enforcing stricter control has shown plateauing of the misuse and consequences in the US. However, various pros and cons are associated with strict control of opioids like shift to more illicit opioid use (like heroin, fentanyl from illicit drug market) and harmful routes of administration like injecting or insufflating. Stricter enforcement of control of pharmaceutical opioids (licit and illicit marketing) with regular monitoring of the outcomes is necessary, also simultaneous ensuring increased availability and accessibility of treatment for opioid dependent individuals. So the debate on prescription opioid control is ongoing and calls for further discussion in how to regulate the control as well as ensure availability to those who are in genuine need of the same.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。